We are live on ! Find out more
CNCE

Concert Pharmaceuticals, Inc.
CNCE

Delisted

CNCE was delisted on the 3rd of March, 2023.

Back to rankings

48 hedge funds and large institutions have $78.7M invested in Concert Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 48 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
48
Holders Change
+48
Holders Change %
–
% of All Funds
1.39%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
48
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCPEM
Bain Capital Public Equity Management
Massachusetts
+$16.2M
2
Franklin Resources
Franklin Resources
California
+$9.7M
3
DM
Deerfield Management
New York
+$8.72M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.2M
5
WSA
Wall Street Associates
California
+$4.53M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
26
Vanguard Group
Pennsylvania
$467K +$490K +34,683 New
SCA
27
SAC Capital Advisors
Connecticut
$432K +$453K +32,118 New
Northern Trust
28
Northern Trust
Illinois
$355K +$373K +26,401 New
SH
29
Scepter Holdings
Texas
$351K +$368K +26,100 New
TCIM
30
TIAA CREF Investment Management
New York
$341K +$358K +25,364 New
Geode Capital Management
31
Geode Capital Management
Massachusetts
$325K +$342K +24,230 New
SIM
32
Spark Investment Management
New York
$251K +$264K +18,700 New
BIM
33
BlackRock Investment Management
Delaware
$229K +$241K +17,052 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$218K +$229K +16,216 New
Millennium Management
35
Millennium Management
New York
$206K +$216K +15,280 New
NFA
36
Nationwide Fund Advisors
Ohio
$198K +$208K +14,746 New
CS
37
Credit Suisse
Switzerland
$174K +$182K +12,910 New
California State Teachers Retirement System (CalSTRS)
38
California State Teachers Retirement System (CalSTRS)
California
$163K +$171K +12,100 New
U
39
UBS
Switzerland
$159K +$167K +11,834 New
BPC
40
Banque Pictet & Cie
Switzerland
$155K +$163K +11,546 New
TA
41
Teachers Advisors
New York
$91K +$95.3K +6,750 New
Barclays
42
Barclays
United Kingdom
$77K +$84.3K +5,971 New
Wells Fargo
43
Wells Fargo
California
$54K +$56.9K +4,030 New
Citigroup
44
Citigroup
New York
$32K +$33.9K +2,404 New
TRCT
45
Tower Research Capital (TRC)
New York
$22K +$23.5K +1,666 New
SSG
46
Summit Securities Group
New York
$13K +$14.1K +1,000 New
WA
47
Winfield Associates
Ohio
$13K +$14.1K +1,000 New
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$4K +$4.24K +300 New
1
2

CNCE Hedge Fund Activity: Q1 2014 in Review

48 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q1 2014, worth a combined $78.7M.

Buyers outnumbered sellers: 48 funds opened new CNCE positions and 0 closed out — a net gain of 48 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Bain Capital Public Equity Management, opening a new position worth an estimated $16.2M.

  • 48 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q1 2014, up from 0 in Q4 2013.
  • Funds reported $78.7M of Concert Pharmaceuticals, Inc. stock for Q1 2014.
  • 48 funds opened new Concert Pharmaceuticals, Inc. positions in Q1 2014 and 0 closed out, a net change of +48 holders.
  • The largest Concert Pharmaceuticals, Inc. buyer in Q1 2014 was Bain Capital Public Equity Management, an estimated $16.2M added.

Based on aggregated 13F filings for Q1 2014.